Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Alimera Sciences, Inc. (ALIM : NSDQ)
 
 • Company Description   
Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company is presently focused on diseases affecting the back of the eye, or retina because it believes these diseases are not well treated with current therapies and represent a significant market opportunity. Its product candidate Iluvien(R) is an intravitreal insert containing fluocinolone acetonide, a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease. Iluvien is in development for the treatment of diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness.

Number of Employees: 154

 
 • Price / Volume Information   
Yesterday's Closing Price: $5.01 Daily Weekly Monthly
20 Day Moving Average: 24,980 shares
Shares Outstanding: 7.00 (millions)
Market Capitalization: $35.08 (millions)
Beta: 1.48
52 Week High: $10.50
52 Week Low: $3.94
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -12.41% -4.10%
12 Week 6.60% 19.80%
Year To Date -2.34% 19.31%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
6310 TOWN SQUARE SUITE 400
-
ALPHARETTA,GA 30005
USA
ph: 678-990-5740
fax: 678-990-5744
scottg@coreir.com http://www.alimerasciences.com
 
 • General Corporate Information   
Officers
Richard S. Eiswirth, Jr. - Chief Executive Officer; President and Director
C. Daniel Myers - Chairman of the Board of Directors
J. Philip Jones - Chief Financial Officer
James Largent - Lead Independent Director
Brian K. Halak, Ph.D. - Director

Peer Information
Alimera Sciences, Inc. (CORR.)
Alimera Sciences, Inc. (RSPI)
Alimera Sciences, Inc. (CGXP)
Alimera Sciences, Inc. (BGEN)
Alimera Sciences, Inc. (GTBP)
Alimera Sciences, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 016259202
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/12/22
Share - Related Items
Shares Outstanding: 7.00
Most Recent Split Date: 11.00 (0.07:1)
Beta: 1.48
Market Capitalization: $35.08 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.61 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.08 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/12/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: 0.59
EPS Growth
vs. Year Ago Period: -34.92%
vs. Previous Quarter: -44.07%
Sales Growth
vs. Year Ago Period: 6.10%
vs. Previous Quarter: -14.76%
ROE
03/31/22 - -
12/31/21 - -
09/30/21 - -
ROA
03/31/22 - -15.00
12/31/21 - -11.21
09/30/21 - -5.88
Current Ratio
03/31/22 - 2.04
12/31/21 - 3.35
09/30/21 - 3.83
Quick Ratio
03/31/22 - 1.90
12/31/21 - 3.14
09/30/21 - 3.63
Operating Margin
03/31/22 - -14.48
12/31/21 - -10.74
09/30/21 - -5.46
Net Margin
03/31/22 - -11.19
12/31/21 - -7.41
09/30/21 - -2.11
Pre-Tax Margin
03/31/22 - -10.45
12/31/21 - -6.66
09/30/21 - -1.52
Book Value
03/31/22 - -3.98
12/31/21 - -3.15
09/30/21 - -2.56
Inventory Turnover
03/31/22 - 2.94
12/31/21 - 2.85
09/30/21 - 2.84
Debt-to-Equity
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Capital
03/31/22 - -
12/31/21 - -
09/30/21 - 96.61
 

Powered by Zacks Investment Research ©